What happens when you take rosuvastatin with coq10?
Rosuvastatin (brand name Crestor) lowers LDL cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. The same pathway is required to synthesize coenzyme Q10 (CoQ10, ubiquinone), a molecule essential for mitochondrial energy production. Blocking the upstream enzyme inevitably reduces downstream CoQ10 production.
Rosuvastatin is a hydrophilic statin, in contrast to lipophilic statins like simvastatin and atorvastatin. This means it is less likely to penetrate non-hepatic tissues such as muscle, and the magnitude of CoQ10 depletion in published studies has generally been somewhat smaller than with lipophilic statins. Nonetheless, plasma CoQ10 reductions in the range of 10% to 40% have been documented with rosuvastatin, depending on dose and duration.
Whether this depletion contributes to statin-associated muscle symptoms (SAMS) is the contested question. Mitochondrial dysfunction is one of the leading mechanistic hypotheses, and a small retrospective case series of patients with prior statin-induced myalgia found that a low-dose, slowly titrated rosuvastatin regimen combined with CoQ10 100 mg daily allowed many previously statin-intolerant patients to tolerate therapy.
Why is this important?
Statin-associated muscle symptoms are the most common reason patients discontinue cholesterol-lowering therapy. Estimates of incidence range from 5% to 30% depending on the population and definition used, and discontinuation is associated with worse cardiovascular outcomes. Rosuvastatin is often used as a switch agent for patients who could not tolerate other statins, but it can still cause muscle symptoms in a meaningful minority of users.
The strongest evidence base for CoQ10 in statin myopathy comes from a 2019 meta-analysis in the Journal of the American Heart Association, which pooled 12 randomized trials with 575 patients across multiple statins (including rosuvastatin) and found a significant reduction in muscle pain, weakness, cramps, and tiredness with supplementation. A 2025 systematic review of seven trials in 389 patients reported similar findings for pain intensity. However, neither analysis showed a change in creatine kinase, the blood marker of muscle injury, and several earlier studies found no symptomatic benefit at all.
For rosuvastatin specifically, the published evidence is thinner than for simvastatin or atorvastatin, but the biological rationale is the same and the trials have included rosuvastatin users. Major lipid guidelines do not formally recommend CoQ10, but many lipid specialists consider it a low-risk empirical trial for patients with bothersome symptoms.
What should you do?
If you take rosuvastatin and feel fine, you do not need to take CoQ10. There is no compelling evidence that supplementation prevents muscle symptoms in asymptomatic patients or improves cardiovascular outcomes.
If you develop muscle aches, cramps, weakness, or tenderness after starting or increasing rosuvastatin, the first move is to talk to your prescriber. Other causes (vitamin D deficiency, hypothyroidism, exertion, drug interactions) should be ruled out, and a creatine kinase blood test can confirm whether actual muscle damage is occurring. If symptoms persist and appear statin-related, a 4-12 week trial of CoQ10 100-200 mg/day with a fat-containing meal is a reasonable option. The ubiquinol form may absorb somewhat better than ubiquinone, especially in older adults.
Rosuvastatin is often a salvage option for patients who could not tolerate other statins. The same retrospective case series mentioned above used a low-dose, gradually titrated rosuvastatin approach (starting at 5 mg every other day) plus CoQ10 100 mg daily, and reported reasonable tolerability. This is not a formally validated protocol, but it illustrates how clinicians have used CoQ10 as part of a rescue strategy.
Which specific products are affected?
The CoQ10 depletion effect is a class effect of all statins, but the magnitude varies. Lipophilic statins (simvastatin, atorvastatin, lovastatin) generally produce larger drops in plasma CoQ10. Hydrophilic statins (rosuvastatin, pravastatin) typically produce smaller but still measurable reductions. The clinical relevance of these differences is unclear.
CoQ10 supplements are sold as ubiquinone (oxidized, less expensive, most-studied) or ubiquinol (reduced, better absorbed, more expensive). Both are interconverted in the body. Doses in clinical trials have ranged from 100 to 600 mg/day, with most protocols using 100-200 mg/day. Third-party-tested products (USP, NSF, ConsumerLab) are preferable because supplement quality varies considerably.
If you take warfarin, be aware that CoQ10 is structurally similar to vitamin K and may slightly reduce warfarin's anticoagulant effect. Tell your prescriber before adding CoQ10 so your INR can be monitored.
The bottom line
Rosuvastatin reduces circulating CoQ10 because both molecules share the same upstream biochemical pathway, though typically to a smaller extent than lipophilic statins like simvastatin. Whether this contributes to muscle symptoms is biologically plausible, and several meta-analyses suggest CoQ10 supplementation may modestly improve statin-associated muscle pain. For symptomatic patients, an empirical 4-12 week trial of 100-200 mg daily with food is a low-risk option that some clinicians use as part of a rescue strategy. Asymptomatic patients do not need to supplement.